The offeror said that the offer price represents a premium of 61.3% to Cordlife’s last-traded price of 15.5 cents on May 9. It also represents a premium of 61.3%, 60.3%, 59.2% and 61.3% to the volume weighted average price (VWAP) of the last one-, three-, six- and 12 month periods. The offer price is 42.9% above Cordlife’s 52-week high traded price of 17.5 cents as well.
Novus Corporate Finance, the independent financial advisor (IFA) appointed to oversee the partial offer of a 10% stake in Cordlife Group by Medeze Group, is of the opinion that the financial terms of the partial offer are not fair and reasonable.
Medeze Group, a leader in Southeast Asia stem cell storage and services market, announced plans to acquire a 10% stake in Cordlife, or 25.63 million shares on May 13, for 25 cents per share.
